SENP7 mediates deSUMOylation and deubiquitination of SP1 to promote lung adenocarcinoma progression and chemoresistance
Zhen Zhang, Qin Huang, Zi-Mei Peng, Xiao-Jian Han, Tao Wang · 2026
Read SENP7 mediates deSUMOylation and deubiquitination of SP1 to promote lung adenocarcinoma progression and chemoresistance by Zhen Zhang, Qin Huang, Zi-Mei Peng, Xiao-Jian Han, Tao Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13571758.txt.
Description
Zhen Zhang and co-authors published a study in 2026 on a protein called SENP7 in lung adenocarcinoma, a common form of lung cancer. The disease kills many people each year, and some patients do not respond to, or become resistant to, existing treatments. Novel therapeutic targets are therefore in strong demand.
The researchers analyzed gene and protein data from large databases and examined lung tissue in the laboratory. SENP7 was markedly more abundant in cancer tissue than in normal lung tissue. High levels were associated with worse outcomes for patients. When the team reduced the protein, cancer growth slowed in cell cultures and in mice. They found that SENP7 protects a second protein, SP1, by removing molecular tags that would mark it for destruction. That action is central both to tumor growth and to resistance to chemotherapy. The pair is proposed as a fresh target.
Catalog record
| CREATOR | Zhen Zhang, Qin Huang, Zi-Mei Peng, Xiao-Jian Han, Tao Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |